CClinicalTrials.gg
CompletedNCT05698667Updated May 6, 2023

Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer

An interventional study of Transoral ultrasound and Transcervical ultrasound in Oropharynx Cancer, Oropharynx Neoplasm and Tonsil Cancer, sponsored by Rigshospitalet, Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Oct 2021, registered Jan 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study was to examine the detection rate and tumor size evaluation in patients with suspected oropharynx cancer using a new technique with transoral ultrasound of the oropharynx. The new technique was compared to Magnetic Resonance Imaging (MRI). The study investigators included patients referred to a tertiary head \& neck cancer center in Copenhagen, Denmark, with suspicion of oropharynx cancer. Patients supplied written informed consent and were included and ultrasound scanned with local anesthesia in the outpatient clinic. Blinded assessment of MRI's was performed for tumor detection and compared to ultrasound with the reference standard being histopathology biopsy results.

Read the detailed description

An explorative diagnostic study was performed at the Department of Otorhinolaryngology, Head \& Neck Surgery, Copenhagen University Hospital - Rigshospitalet, Denmark from October 1st, 2021, to April 30th, 2022. The study investigators invited adult patients from the outpatient cancer clinic referred with a suspicion of oropharynx cancer to participate in the study. At the study investigators' center, all head \& neck cancer patients receive diagnostic work-up which includes clinical exam, flexible laryngoscopy with narrow-band imaging, surgeon-performed neck ultrasound and biopsy and/or cytology with same-day results. Patients were enrolled after verbal and written consent and were offered an ultrasound examination of the oropharynx as an addition to the standard diagnostic workup in the outpatient clinic. All included patients also received an MRI of the head and neck. Clinical data including age, sex, smoking habits, alcohol consumption, date of MRI scan, and histopathology results were obtained from medical charts after inclusion.

Interventions included transoral ultrasound of the tonsils and base of tongue, conducted with BK5000 ultrasound machines using the X18L5s "hockey stick" transducer. Transcervical ultrasound was also performed in patients where a tongue base cancer was most likely. Standard linear neck transducers (X18L5) or a curved 9C2 transducer was used. The tonsils and tongue base were scanned in two planes if possible, and doppler flow was recorded as well. Ultrasound images were stored as video clips.

The detection of tumors with ultrasound was recorded as "positive" if a well-defined tumor was seen that was clearly visualized compared to the contralateral side. A "negative" result was given if no tumors were suspected on either side. An "inconclusive" result was given if a tumor was not clear, but there was suspicious asymmetry visualized. The anatomical sub-location of tumors were stratified into right and left tonsil, tongue base, overlapping tonsil and tongue base, and "other" sub-locations. "Other" sub-locations included the soft palate, uvula, oropharynx posterior wall, vallecula, anterior pharyngeal arch and posterior pharyngeal arch.

MRI was used as the reference test. An expert neuroradiologist blinded to ultrasound results and histopathology rated all tests for tumor detection in the oropharynx and tumor size in detected tumors.

Statistical analysis:

Tumor detection of oropharynx ultrasound and MRI will be compared using the histopathologic diagnosis (cancer or benign) as reference standard to calculate sensitivity, specificity, positive- and negative predictive values (PPV, NPV).

Inconclusive tests will be analyzed as a positive result due to the clinical consequences often leading to diagnostic tonsillectomy.

McNemar's test for differences between sensitivity, specificity, PPV and NPV between ultrasound and MRI will be calculated.

The greatest tumor diameter will be compared between ultrasound and MRI using scatter plots and the Pearson's R correlation coefficient. Tumor volumes calculated using the formula for an ellipse: π/6 * craniocaudal * anteroposterior * mediolateral will be compared. Statistical analysis will be performed using R software version 4.2.2.

02

Conditions studied

  • Oropharynx Cancer
  • Oropharynx Neoplasm
  • Tonsil Cancer
  • Tonsil Neoplasm
  • Tonsil Hypertrophy
  • Tonsil Lymphoma
  • Base of Tongue Tumor
  • Base of Tongue Carcinoma
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 26 is below the median of 50 across 7,253 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Rigshospitalet, Denmark is the lead sponsor of 1,017 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Visible and/or palpable tumor or asymmetry of the tonsils, tongue base or oropharynx.
  • Subjective symptoms of oropharynx cancer including dysphagia, odynophagia and/or referred otalgia.

Exclusion criteria

Exclusion Criteria:

  • Unable to understand Danish or English.
  • Unable to provide written informed consent.
  • Age younger than 18 years.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Oropharynx Ultrasound

    Transoral and transcervical ultrasound of the oropharynx, including the tonsils and tongue base.

    Diagnostic Test: Transoral ultrasound · Diagnostic Test: Transcervical ultrasound

Interventions

  • Diagnostic testTransoral ultrasound

    Under local anesthetic with xylocaine spray in the oropharynx, the tonsils and tongue base are scanned with small-footprint, high-frequency ultrasound transducers (such as the 18XL5s hockey-stick from BK Medical)

  • Diagnostic testTranscervical ultrasound

    The tongue base and tonsils are scanned externally via the neck, where a (preferably low-frequency) transducer is placed onto the skin above the hyoid bone to visualize the tongue base. The tonsils are visualized adjacent to the tongue base on either side and are located deep to the submandibular glands in a oblique coronal plane.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with oropharynx cancer detected by ultrasound compared to MRI

    Patients with cancer (histopathology verified) correctly detected by a positive ultrasound or MRI test result.

    Time frame: Within two weeks.

Secondary outcomes

  1. Greatest tumor diameter compared between ultrasound and MRI.

    Greatest tumor diameter measured in millimeters.

    Time frame: 1 day

  2. Proportion of patients without oropharynx cancer detected by ultrasound compared to MRI

    Patients with benign tonsillar asymmetry (histopathology verified) correctly detected by a negative ultrasound or MRI test result.

    Time frame: Within three months.

07

Study locations

1 site
  • Department of Otorhinolaryngology, Head & Neck Surgery & Audiology
    Copenhagen, 2100, Denmark
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05698667
Lead sponsor
Rigshospitalet, Denmark
Collaborators
The Novo Nordic Foundation
Responsible party
Martin Garset-Zamani, MD (Principal Investigator, Rigshospitalet, Denmark) — Principal investigator
First posted
Jan 26, 2023
Start date
Oct 1, 2021
Primary completion
May 1, 2022
Completion
May 1, 2022
Last update
May 6, 2023

Study contacts

Tobias Todsen, MD, PhD
study director · Rigshospitalet, Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion